Human and Animal Tumour Efficacy Evaluation: Endpoints and Methods from a Translational Perspective

Open Access

Issue		BIO Web Conf. Volume 237, 2026 2026 8^th International Conference on Biotechnology and Biomedicine (ICBB 2026)


Article Number		02026
Number of page(s)		11
Section		Pharmacology, Natural Products and Drug Delivery
DOI		https://doi.org/10.1051/bioconf/202623702026
Published online		10 June 2026

Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711–6. doi:10.1038/nrd1470 [Google Scholar]
Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022 Jan 12;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059 [CrossRef] [PubMed] [Google Scholar]
Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019 Apr 1;20(2):273–86. doi:10.1093/biostatistics/kxx069 [Google Scholar]
Frühwein H, Paul NW. “Lost in translation?” Animal research in the era of precision medicine. J Transl Med. 2025 Feb 4;23(1):152. doi:10.1186/s12967-025-06084-3 [Google Scholar]
De Vleeschauwer SI, van de Ven M, Oudin A, Debusschere K, Connor K, Byrne AT, et al. OBSERVE: guidelines for the refinement of rodent cancer models. Nat Protoc. 2024 Sep;19(9):2571–96. doi:10.1038/s41596-024-00998-w PubMed PMID: 38992214. [Google Scholar]
Merino M, Kasamon Y, Theoret M, Pazdur R, Kluetz P, Gormley N. Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival. J Clin Oncol. 2023 May 20;41(15):2706–12. doi:10.1200/JCO.23.00225 PubMed PMID: 36930853; PubMed Central PMCID: PMC10414695. [Google Scholar]
Jain A, Stebbing J. The Relationship Between Response Rate and Survival Benefits in Randomized Immunotherapy Studies. Cancers. 2025 Jan;17(3):495. doi:10.3390/cancers17030495 [Google Scholar]
Tibau A, Romano A, Liu ITT, Han J, Cliff ERS, Kesselheim AS. Assessing outcomes emerging after conversion to regular approval for cancer drug indications granted accelerated approval, 1992-2021. J Natl Cancer Inst. 2025 Oct 1;117(10):2103–11. doi:10.1093/jnci/djaf195 PubMed PMID: 40690366. [Google Scholar]
Park HJ, Kim KW, Pyo J, Suh CH, Yoon S, Hatabu H, et al. Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. Radiology. 2020 Oct;297(1):87–96. doi:10.1148/radiol.2020200443 [Google Scholar]
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 2017 Mar 1;18(3):e143–52. doi:10.1016/S1470-2045(17)30074-8 PubMed PMID: 28271869. [Google Scholar]
Hendriks H. Advancing oncology drug development: Innovative approaches to enhance success rates while reducing animal testing. Biochim Biophys Acta Rev Cancer. 2025 Nov;1880(6):189467. doi:10.1016/j.bbcan.2025.189467 PubMed PMID: 41046061. [Google Scholar]
Nicotra R, Lutz C, Messal HA, Jonkers J. Rat Models of Hormone Receptor-Positive Breast Cancer. J Mammary Gland Biol Neoplasia. 2024 Jun 24;29(1):12. doi:10.1007/s10911-024-09566-0 [Google Scholar]
Chuprin J, Buettner H, Seedhom MO, Greiner DL, Keck JG, Ishikawa F, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023 Mar;20(3):192–206. doi:10.1038/s41571-022-00721-2 PubMed PMID: 36635480; PubMed Central PMCID: PMC10593256. [Google Scholar]
Tatom Z, Miles MF, Palmer AA. Fifteen years of the Diversity Outbred mouse model: a review. Mamm Genome. 2026 Jan 28;37(1):28. doi:10.1007/s00335-026-10196-6 PubMed PMID: 41606199; PubMed Central PMCID: PMC12852284. [Google Scholar]
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009 Jan 1;Response assessment in solid tumours (RECIST): Version 1.1 and supporting papers 45(2):228–47. doi:10.1016/j.ejca.2008.10.026 [Google Scholar]
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. Journal of Nuclear Medicine. 2009 May 1;50(Suppl 1):122S- 150S. doi:10.2967/jnumed.108.057307 PubMed PMID: 19403881. [Google Scholar]
Litière S, Bogaerts J. Imaging endpoints for clinical trial use: a RECIST perspective. J Immunother Cancer. 2022 Nov 24;10(11):e005092. doi:10.1136/jitc-2022-005092 PubMed PMID: 36424032; PubMed Central PMCID: PMC9693866. [Google Scholar]
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Sig Transduct Target Ther. 2024 May 20;9(1):132. doi:10.1038/s41392-024-01823-2 [Google Scholar]
Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, et al. Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI- AD): a biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol. 2025 May;26(5):641–53. doi:10.1016/S1470-2045(25)00139-1 PubMed PMID: 40250457. [Google Scholar]
Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, et al. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB- RECIST). Annals of Oncology. 2024 Mar 1;35(3):267–75. doi:10.1016/j.annonc.2023.12.007 [Google Scholar]
Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Sig Transduct Target Ther. 2024 Dec 2;9(1):336. doi:10.1038/s41392-024-02021-w [Google Scholar]
Perez J, Kerr KM, Baker B, Fang F, Li J, McDonald J, et al. Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non- Small Cell Lung Cancer Management With Cemiplimab. JCO Precis Oncol. 2025 Sep;9:e2500177. doi:10.1200/PO-25-00177 PubMed PMID: 40991883; PubMed Central PMCID: PMC12487655. [Google Scholar]
Kerr KM, Bubendorf L, Lopez-Rios F, Khalil F, Roy-Chowdhuri S, Joubert P, et al. Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology. 2024 Feb;84(3):429–39. doi:10.1111/his.15078 PubMed PMID: 37957137. [Google Scholar]
Ballhausen A, Swoboda S, Horst D, Fruehauf S, Graeven U, Müller L, et al. Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial. Clin Cancer Res. 2025 Oct 1;31(19):4049–58. doi:10.1158/1078-0432.CCR-25-0879 PubMed PMID: 40736443. [Google Scholar]
Tregear M, Visco F. Outcomes that matter to patients with cancer: living longer and living better. EClinicalMedicine. 2024 Oct;76:102833. doi:10.1016/j.eclinm.2024.102833 PubMed PMID: 39309725; PubMed Central PMCID: PMC11415949. [Google Scholar]
Huang B, Tian L. Utilizing restricted mean duration of response for efficacy evaluation of cancer treatments. Pharmaceutical Statistics. 2022;21(5):865–78. doi:10.1002/pst.2198 [Google Scholar]
Jayathilaka B, Mian F, Franchini F, Au-Yeung G, IJzerman M. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br J Cancer. 2025 Jan;132(1):51–7. doi:10.1038/s41416-024-02887-1 PubMed PMID: 39489880; PubMed Central PMCID: PMC11723908. [Google Scholar]
Liu M, Yang X. Patient-derived xenograft models: Current status, challenges, and innovations in cancer research. Genes Dis. 2025 Sep;12(5):101520. doi:10.1016/j.gendis.2025.101520 PubMed PMID: 40548062; PubMed Central PMCID: PMC12179623. [Google Scholar]
Sert NP du, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, et al. Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLOS Biology. 2020 Jul 14;18(7):e3000411. doi:10.1371/journal.pbio.3000411 [Google Scholar]
Barbosa GR, de Souza AM, Silva PF, Fávero CS, de Oliveira JL, Carvalho HF, et al. Zebrafish as a Model for Translational Immuno-Oncology. J Pers Med. 2025 Jul 11;15(7):304. doi:10.3390/jpm15070304 PubMed PMID: 40710421; PubMed Central PMCID: PMC12298638. [Google Scholar]
Jin X, Kaes J, Van Slambrouck J, Inci I, Arni S, Geudens V, et al. A Comprehensive Review on the Surgical Aspect of Lung Transplant Models in Mice and Rats. Cells. 2022 Jan;11(3):480. doi:10.3390/cells11030480 [Google Scholar]
Bruzgo-Grzybko M, Kalita IS, Olichwier AJ, Bielicka N, Chabielska E, Gromotowicz-Poplawska A. Preclinical PET and SPECT Imaging in Small Animals: Technologies, Challenges and Translational Impact. Cells. 2025 Dec 31;15(1):73. doi:10.3390/cells15010073 PubMed PMID: 41511356; PubMed Central PMCID: PMC12786211. [Google Scholar]
Serkova NJ, Glunde K, Haney CR, Farhoud M, De Lille A, Redente EF, et al. Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer. Cancer Res. 2021 Mar 1;81(5):1189–200. doi:10.1158/0008-5472.CAN-20-0373 [Google Scholar]
Xu X, Tseng YP, Deghhani H, Hardy L, Tong Z, Guo G, et al. High precision fluorescence tomography system for pre-clinical radiation research: system design and validation. Phys Med Biol. 2025 Dec 17;70(24). doi:10.1088/1361-6560/ae281b PubMed PMID: 41343972. [Google Scholar]
McDougald W, Vanhove C, Lehnert A, Lewellen B, Wright J, Mingarelli M, et al. Standardization of Preclinical PET/CT Imaging to Improve Quantitative Accuracy, Precision, and Reproducibility: A Multicenter Study. Journal of Nuclear Medicine. 2020 Mar 1;61(3):461–8. doi:10.2967/jnumed.119.231308 PubMed PMID: 31562220. [Google Scholar]
Preclinical SPECT and PET: Joint EANM and ESMI procedure guideline for implementing an efficient quality control programme | European Journal of Nuclear Medicine and Molecular Imaging | Springer Nature Link [Internet]. [cited 2026 Jan 27]. Available from: https://link.springer.com/article/10.1007/s00259-024-06824-5 [Google Scholar]
Kazim M, Ganguly A, Malespini SM, Thang L, Patel NL, Kim C, et al. Granzyme-targeting quenched activity-based probes for assessing tumor response to immunotherapy. bioRxiv. 2025 Mar 15;2025.03.13.643086. doi:10.1101/2025.03.13.643086 PubMed PMID: 40161750; PubMed Central PMCID: PMC11952571. [Google Scholar]
Chau CH, Rixe O, McLeod H, Figg WD. Validation of Analytic Methods for Biomarkers Used in Drug Development. Clin Cancer Res. 2008 Sep 30;14(19):5967–76. doi:10.1158/1078-0432.CCR-07-4535 [Google Scholar]
Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006 Aug;24(8):971–83. doi:10.1038/nbt1235 [Google Scholar]
Taube JM, Sunshine JC, Angelo M, Akturk G, Eminizer M, Engle LL, et al. Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing. J Immunother Cancer. 2025 Jan 8;13(1):e008875. doi:10.1136/jitc-2024-008875 PubMed PMID: 39779210; PubMed Central PMCID: PMC11749220. [Google Scholar]
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014 Dec 5;15(12):550. doi:10.1186/s13059-014-0550-8 [Google Scholar]
Elhanani O, Ben-Uri R, Keren L. Spatial profiling technologies illuminate the tumor microenvironment. Cancer Cell. 2023 Mar 13;41(3):404–20. doi:10.1016/j.ccell.2023.01.010 PubMed PMID: 36800999. [Google Scholar]
Seep L, Grein S, Splichalova I, Ran D, Mikhael M, Hildebrand S, et al. From Planning Stage Towards FAIR Data: A Practical Metadatasheet For Biomedical Scientists. Sci Data. 2024 May 22;11(1):524. doi:10.1038/s41597-024-03349-2 [Google Scholar]
Chen DS, Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity. 2013 Jul 25;39(1):1–10. doi:10.1016/j.immuni.2013.07.012 [Google Scholar]
Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, et al. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer. 2025 Mar 7;13(3):e010928. doi:10.1136/jitc-2024-010928 PubMed PMID: 40054999; PubMed Central PMCID: PMC11891540. [Google Scholar]
Cossarizza A, Chang HD, Radbruch A, Abrignani S, Addo R, Akdis M, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). European Journal of Immunology. 2021;51(12):2708–3145. doi:10.1002/eji.202170126 [Google Scholar]
Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science. 2011 Mar 25;331(6024):1565–70. doi:10.1126/science.1203486 [Google Scholar]
Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. 1958 Jun 1;53(282):457–81. doi:10.1080/01621459.1958.10501452 [Google Scholar]
Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017 Oct 16;17(1):684. doi:10.1186/s12885-017-3677-7 [Google Scholar]
Lilue J, Doran AG, Fiddes IT, Abrudan M, Armstrong J, Bennett R, et al. Sixteen diverse laboratory mouse reference genomes define strain- specific haplotypes and novel functional loci. Nat Genet. 2018 Nov;50(11):1574–83. doi:10.1038/s41588-018-0223-8 [Google Scholar]
Nadeau JH, Auwerx J. The virtuous cycle of human genetics and mouse models in drug discovery. Nat Rev Drug Discov. 2019 Apr;18(4):255–72. doi:10.1038/s41573-018-0009-9 [Google Scholar]
Medetgul-Ernar K, Davis MM. Standing on the shoulders of mice. Immunity. 2022 Aug 9;55(8):1343–53. doi:10.1016/j.immuni.2022.07.008 PubMed PMID: 35947979. [Google Scholar]
Tong L, Cui W, Zhang B, Fonseca P, Zhao Q, Zhang P, et al. Patient-derived organoids in precision cancer medicine. Med. 2024 Nov 8;5(11):1351–77. doi:10.1016/j.medj.2024.08.010 PubMed PMID: 39341206. [Google Scholar]
Wang X, Zhao J, Marostica E, Yuan W, Jin J, Zhang J, et al. A pathology foundation model for cancer diagnosis and prognosis prediction. Nature. 2024 Oct;634(8035):970–8. doi:10.1038/s41586-024-07894-z PubMed PMID: 39232164; PubMed Central PMCID: PMC12186853. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.